CRISPR Therapeutics
![Vertex Readies for exa-cel Launch, Cautiously Eyes Enormous Opportunity](https://pharmtales.com/wp-content/uploads/2023/11/Vertex-Gears-Up-for-exa-cel-Launch-Acknowledges-Vast-Opportunity-with-Cautious-Outlook.jpg)
Vertex Gears Up for exa-cel Launch, Acknowledges Vast Opportunity with Cautious Outlook
Anika Sharma
After a prolonged journey in development, the first CRISPR-based gene editing therapy has recently received approval from an FDA advisory ...
![Groundbreaking CRISPR Therapy Gets FDA Panel Nod](https://pharmtales.com/wp-content/uploads/2023/11/FDA-Panel-Approves-First-CRISPR-Therapy-After-Rigorous-Safety-Evaluations.jpg)
FDA Panel Approves First CRISPR Therapy After Rigorous Safety Evaluations
Anika Sharma
The FDA advisory committee has expressed satisfaction with the evaluation of potential off-target effects conducted by CRISPR Therapeutics and Vertex ...
![CRISPR-Vertex’s gene editing therapy faces FDA committee review](https://pharmtales.com/wp-content/uploads/2023/10/CRISPR-Vertexs-gene-editing-therapy-faces-FDA-committee-review.jpg)
CRISPR-Vertex’s gene editing therapy faces FDA committee review
Anika Sharma
A significant milestone in the pharmaceutical industry is on the horizon as an FDA advisory committee prepares to review the ...